Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07659795 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

Study acronym: TARGET-D 203
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 22 to 23
  2. Study sites: 21 to 22
  3. Study sites: 19 to 21
  4. Study sites: 18 to 19
  5. Study sites: 17 to 18
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 16 to 17
  2. Study sites: 14 to 16 Eligibility criteria expanded, about 19 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 19 words
  3. Study sites: 13 to 14v10
  4. Study sites: 12 to 13v9
  5. Study sites: 11 to 12v8
  6. Study sites: 10 to 11v7
  7. Study sites revised (10)v6 See this version in full on ClinicalTrials.gov ↗
  8. Study sites: 8 to 10 Start date changed from estimate of Jul 2026 to Jul 28, 2026v5 Show 1 more changeShow less
    • Start date changed from estimate of Jul 2026 to Jul 28, 2026
  9. Study sites: 7 to 8v4
  10. Study sites: 5 to 7v3
  1. Recruitment opened Trial sites expanded: 0 → 5 locations · Start date: Jun 2026 to Jul 2026v2 Show 2 more changesShow less
    • Trial sites expanded: 0 → 5 locations
    • Start date: Jun 2026 to Jul 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Trial Details
NCT Number NCT07659795
Lead Sponsor Verastem, Inc.
Conditions Colorectal Cancer
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov